Amarin reports REDUCE-IT Legacy data

• Amarin presented new post hoc REDUCE-IT Legacy analysis data from the cardiovascular outcomes trial at ESC Congress 2026.
• High-adhering patients receiving icosapent ethyl showed an approximately 29%–30% relative risk reduction in the primary endpoint versus placebo.
• The analysis examined whether cardiovascular benefits continued after some patients stopped treatment.

Amarin (NASDAQ:AMRN) reported new post hoc REDUCE-IT Legacy analysis data showing that patients with high adherence to icosapent ethyl experienced an approximately 29%–30% relative reduction in the primary cardiovascular endpoint compared with placebo.

The analysis was based on the REDUCE-IT cardiovascular outcomes trial, which enrolled 8,179 statin-treated patients with elevated triglycerides and high cardiovascular risk, compared with the original intention-to-treat population that showed a 25% relative risk reduction.

The post hoc analysis examined 6,921 high-adhering patients who remained on icosapent ethyl for at least 1.5 years and included a secondary prevention group of 1,318 patients who discontinued study treatment after an average of 2.3 years.

The company stated that the findings provide additional analysis of cardiovascular outcomes associated with icosapent ethyl treatment.

Amarin’s REDUCE-IT program evaluates icosapent ethyl, marketed as VASCEPA in the United States and VAZKEPA in Europe, as a therapy for reducing cardiovascular risk in eligible high-risk patients.

The company presented the new analyses at the European Society of Cardiology Congress 2026, alongside other research examining icosapent ethyl and eicosapentaenoic acid-related cardiovascular data.